EyePoint (EYPT) Return on Capital Employed (2011 - 2026)
EyePoint (EYPT) reported Return on Capital Employed of 97.64% for Q1 2026, down 5138.0% on a YoY basis from 1.94% in Q1 2025, and down 8.62% sequentially from 89.89% in Q4 2025.
EyePoint (EYPT) Return on Capital Employed (2011 - 2026) Analysis & Trends
EyePoint (EYPT) has 16 years of Return on Capital Employed data on file, last reported at 97.64% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 5138.0% year-over-year to 97.64%; the trailing twelve-month figure through Mar 2026 stood at 97.64% (down 5138.0% YoY), and the FY2025 full-year result was 68.73%, down 2555.0% from the prior year.
- Return on Capital Employed declined to 97.64% in Q1 2026, from 89.89% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 28.21% in Q1 2022 to a low of 110.64% in Q2 2023.
- A 5-year average of 60.45% and a median of 46.95% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed sank 7618 bps in 2023 and soared 7338 bps in 2024, its largest moves.
- Tracing EYPT's Return on Capital Employed over 5 years: stood at 60.06% in 2022, then jumped by 36 bps to 38.62% in 2023, then retreated by 22 bps to 46.95% in 2024, then sank by 91 bps to 89.89% in 2025, then decreased by 9 bps to 97.64% in 2026.
- Business Quant data shows EYPT's Return on Capital Employed at 97.64% in Q1 2026, 89.89% in Q4 2025, and 88.63% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 | -97.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.64% |
| Dec 31, 2025 | -89.89% |
| Sep 30, 2025 | -88.63% |
| Jun 30, 2025 | -63.30% |
| Mar 31, 2025 | -46.26% |
| Dec 31, 2024 | -46.95% |
| Sep 30, 2024 | -44.34% |
| Jun 30, 2024 | -37.26% |
| Mar 31, 2024 | -31.05% |
| Dec 31, 2023 | -38.62% |
| Sep 30, 2023 | -98.55% |
| Jun 30, 2023 | -110.64% |
| Mar 31, 2023 | -73.38% |
| Dec 31, 2022 | -60.06% |
| Sep 30, 2022 | -38.37% |
| Jun 30, 2022 | -34.47% |
| Mar 31, 2022 | -28.21% |
| Dec 31, 2021 | -28.77% |
| Sep 30, 2021 | -32.53% |
| Jun 30, 2021 | -21.96% |